Scar revision review

Archives of Facial Plastic Surgery

Volumn 14, Issue 3, 2012, Pages 162-174

  Thomas, J Regan ^a   Somenek, Michael ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIMETABOLITE; ANTINEOPLASTIC ANTIBIOTIC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INTERFERON INDUCING AGENT; PLANT EXTRACT; SILICONE GEL; TGFB3 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA3;

HUMAN; LOW LEVEL LASER THERAPY; METHODOLOGY; PHYTOTHERAPY; RADIOTHERAPY; REVIEW; SCAR; SKIN ABRASION; SKIN SURGERY; WOUND HEALING;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-INFLAMMATORY AGENTS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES; CICATRIX; DERMABRASION; DERMATOLOGIC SURGICAL PROCEDURES; HUMANS; INTERFERON INDUCERS; LASER THERAPY; PHYTOTHERAPY; PLANT EXTRACTS; RADIOTHERAPY; SILICONE GELS; TRANSFORMING GROWTH FACTOR BETA3; WOUND HEALING;

EID: 84863885862     PISSN: 15212491     EISSN: 15383660     Source Type: Journal    
DOI: 10.1001/archfacial.2012.223     Document Type: Review

References (135)

1. Katz BE. Silicone gel sheeting in scar therapy. Cutis. 1995;56(1):65-67.
2. Diegelmann RF, Bryant CP, Cohen IK. Tissue alpha-globulins in keloid formation. Plast Reconstr Surg. 1977;59(3):418-423.
3. Ardehali B, Nouraei SA, Van Dam H, Dex E, Wood S, Nduka C. Objective assessment of keloid scars with three-dimensional imaging: quantifying response to intralesional steroid therapy. Plast Reconstr Surg. 2007;119(2): 556-561. (Pubitemid 46142941)
4. Chowdri NA, Masarat M, Mattoo A, Darzi MA. Keloids and hypertrophic scars: results with intraoperative and serial postoperative corticosteroid injection therapy. Aust N Z J Surg. 1999;69(9):655-659. (Pubitemid 29422139)
5. Chen MA, Davidson TM. Scar management: prevention and treatment strategies. Curr Opin Otolaryngol Head Neck Surg. 2005;13(4):242-247. (Pubitemid 41003852)
6. Wendling J, Marchand A, Mauviel A, Verrecchia F. 5-fluorouracil blocks transforming growth factor-beta-induced alpha 2 type I collagen gene (COL1A2) expression in human fibroblasts via c-Jun NH2-terminal kinase/activator protein-1 activation. Mol Pharmacol. 2003;64(3):707-713. (Pubitemid 37048575)
7. Fitzpatrick RE. Treatment of inflamed hypertrophic scars using intralesional 5-FU. Dermatol Surg. 1999;25(3):224-232. (Pubitemid 29146991)
8. Manuskiatti W, Fitzpatrick RE. Treatment response of keloidal and hypertrophic sternotomy scars: comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. Arch Dermatol. 2002;138(9):1149-1155. (Pubitemid 35025686)
9. Apikian M, Goodman G. Intralesional 5-fluorouracil in the treatment of keloid scars. Australas J Dermatol. 2004;45(2):140-143. (Pubitemid 38607932)
10. Darougheh A, Asilian A, Shariati F. Intralesional triamcinolone alone or in combination with 5-fluorouracil for the treatment of keloid and hypertrophic scars. Clin Exp Dermatol. 2009;34(2):219-223.
11. Asilian A, Darougheh A, Shariati F. New combination of triamcinolone, 5-fluorouracil, and pulsed-dye laser for treatment of keloid and hypertrophic scars. Dermatol Surg. 2006;32(7):907-915. (Pubitemid 44034368)
12. Kontochristopoulos G, Stefanaki C, Panagiotopoulos A, et al. Intralesional 5-fluorouracil in the treatment of keloids: an open clinical and histopathologic study. J Am Acad Dermatol. 2005;52(3, pt 1):474-479.
13. Haurani MJ, Foreman K, Yang JJ, Siddiqui A. 5-Fluorouracil treatment of problematic scars. Plast Reconstr Surg. 2009;123(1):139-151.
14. Hatamipour E, Mehrabi S, Hatamipour M, Ghafarian Shirazi HR. Effects of combined intralesional 5-fluorouracil and topical silicone in prevention of keloids: a double blind randomized clinical trial study. Acta Med Iran. 2011;49(3): 127-130.
15. Miller RL, Gerster JF, Owens ML, Slade HB, Tomai MA. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol. 1999;21(1):1-14. (Pubitemid 29097684)
16. Berman B, Kaufman J. Pilot study of the effect of postoperative imiquimod 5% cream on the recurrence rate of excised keloids. J Am Acad Dermatol. 2002; 47(4)(suppl):S209-S211.
17. Martin-García RF, Busquets AC. Postsurgical use of imiquimod 5% cream in the prevention of earlobe keloid recurrences: results of an open-label, pilot study. Dermatol Surg. 2005;31(11, pt 1):1394-1398.
18. Cação FM, Tanaka V, Messina MC. Failure of imiquimod 5% cream to prevent recurrence of surgically excised trunk keloids. Dermatol Surg. 2009;35(4): 629-633.
19. Malhotra AK, Gupta S, Khaitan BK, Sharma VK. Imiquimod 5% cream for the prevention of recurrence after excision of presternal keloids. Dermatology. 2007; 215(1):63-65. (Pubitemid 46976016)
20. Augusti KT. Therapeutic values of onion (Allium cepa L) and garlic (Allium sativum L). Indian J Exp Biol. 1996;34(7):634-640. (Pubitemid 126496487)
21. Saulis AS, Mogford JH, Mustoe TA. Effect of Mederma on hypertrophic scarring in the rabbit ear model. Plast Reconstr Surg. 2002;110(1):177-186.
22. Jackson BA, Shelton AJ. Pilot study evaluating topical onion extract as treatment for postsurgical scars. Dermatol Surg. 1999;25(4):267-269. (Pubitemid 29191310)
23. Zurada JM, Kriegel D, Davis IC. Topical treatments for hypertrophic scars. J Am Acad Dermatol. 2006;55(6):1024-1031. (Pubitemid 44716469)
24. Hosnuter M, Payasli C, Isikdemir A, Tekerekoglu B. The effects of onion extract on hypertrophic and keloid scars. J Wound Care. 2007;16(6):251-254.
25. Shumer SM, O'Keefe EJ. Bleomycin in the treatment of recalcitrant warts. J Am Acad Dermatol. 1983;9(1):91-96. (Pubitemid 13068682)
26. Bennett JM, Reich SD. Bleomycin. Ann Intern Med. 1979;90(6):945-948. (Pubitemid 9229633)
27. Templeton SF, Solomon AR, Swerlick RA. Intradermal bleomycin injections into normal human skin: a histopathologic and immunopathologic study. Arch Dermatol. 1994;130(5):577-583. (Pubitemid 24150935)
28. Hendricks T, Martens MF, Huyben CM, Wobbes T. Inhibition of basal and TGF beta-induced fibroblast collagen synthesis by antineoplastic agents: implications for wound healing. Br J Cancer. 1993;67(3):545-550. (Pubitemid 23077650)
29. Tounekti O, Pron G, Belehradek JJ Jr, Mir LM. Bleomycin, an apoptosismimetic drug that induces two types of cell death depending on the number of molecules internalized. Cancer Res. 1993;53(22):5462-5469. (Pubitemid 23342168)
30. España A, Solano T, Quintanilla E. Bleomycin in the treatment of keloids and hypertrophic scars by multiple needle punctures. Dermatol Surg. 2001;27 (1):23-27. (Pubitemid 32107611)
31. Saray Y, Güleç AT. Treatment of keloids and hypertrophic scars with dermojet injections of bleomycin: a preliminary study. Int J Dermatol. 2005;44(9): 777-784. (Pubitemid 41301018)
32. Aggarwal H, Saxena A, Lubana PS, Mathur RK, Jain DK. Treatment of keloids and hypertrophic scars using bleom. J Cosmet Dermatol. 2008;7(1):43-49. (Pubitemid 351228166)
33. Bhatt N, Alster TS. Laser surgery in dark skin. Dermatol Surg. 2008;34(2):184-195.
34. Apfelberg DB, Maser MR, White DN, Lash H. Failure of carbon dioxide laser excision of keloids. Lasers Surg Med. 1989;9(4):382-388. (Pubitemid 19190411)
35. Alster TS. Cutaneous resurfacing with CO2 and erbium: YAG lasers: preoperative, intraoperative, and postoperative considerations. Plast Reconstr Surg. 1999; 103(2):619-634.
36. Alster TS, West TB. Resurfacing of atrophic facial acne scars with a highenergy, pulsed carbon dioxide laser. Dermatol Surg. 1996;22(2):151-155. (Pubitemid 26069620)
37. Tanzi EL, Alster TS. Treatment of atrophic facial acne scars with a dual-mode Er:YAG laser. Dermatol Surg. 2002;28(7):551-555. (Pubitemid 34816031)
38. Alster TS, Williams CM. Treatment of keloid sternotomy scars with 585 nm flashlamp-pumped pulsed-dye laser. Lancet. 1995;345(8959):1198-1200.
39. McCraw JB, McCraw JA, McMellin A, Bettencourt N. Prevention of unfavorable scars using early pulse dye laser treatments: a preliminary report. Ann Plast Surg. 1999;42(1):7-14. (Pubitemid 29044785)
40. Nouri K, Jimenez GP, Harrison-Balestra C, Elgart GW. 585-nm pulsed dye laser in the treatment of surgical scars starting on the suture removal day. Dermatol Surg. 2003;29(1):65-73. (Pubitemid 36114732)
41. Kuo YR, Jeng SF, Wang FS, et al. Flashlamp pulsed dye laser (PDL) suppression of keloid proliferation through down-regulation of TGF-beta1 expression and extracellular matrix expression. Lasers Surg Med. 2004;34(2):104-108.
42. Alster TS, Nanni CA. Pulsed dye laser treatment of hypertrophic burn scars. Plast Reconstr Surg. 1998;102(6):2190-2195. (Pubitemid 28518549)
43. Reiken SR, Wolfort SF, Berthiaume F, Compton C, Tompkins RG, Yarmush ML. Control of hypertrophic scar growth using selective photothermolysis. Lasers Surg Med. 1997;21(1):7-12. (Pubitemid 27284069)
44. Alster TS, Handrick C. Laser treatment of hypertrophic scars, keloids, and striae. Semin Cutan Med Surg. 2000;19(4):287-292. (Pubitemid 32042983)
45. Manuskiatti W, Wanitphakdeedecha R, Fitzpatrick RE. Effect of pulse width of a 595-nm flashlamp-pumped pulsed dye laser on the treatment response of keloidal and hypertrophic sternotomy scars. Dermatol Surg. 2007;33(2):152-161. (Pubitemid 46208105)
46. Nouri K, Elsaie ML, Vejjabhinanta V, et al. Comparison of the effects of shortand long-pulse durations when using a 585-nm pulsed dye laser in the treatment of new surgical scars. Lasers Med Sci. 2010;25(1):121-126.
47. Alster T, Zaulyanov L. Laser scar revision: a review. Dermatol Surg. 2007;33(2): 131-140. (Pubitemid 46208102)
48. Abergel RP, Meeker CA, Lam TS, Dwyer RM, Lesavoy MA, Uitto J. Control of connective tissue metabolism by lasers: recent developments and future prospects. J Am Acad Dermatol. 1984;11(6):1142-1150. (Pubitemid 15210496)
49. Sherman R, Rosenfeld H. Experience with the Nd:YAG laser in the treatment of keloid scars. Ann Plast Surg. 1988;21(3):231-235.
50. Kumar K, Kapoor BS, Rai P, Shukla HS. In-situ irradiation of keloid scars with Nd:YAG laser. J Wound Care. 2000;9(5):213-215.
51. Cho SB, Park SJ, Kim JS, Kim MJ, Bu TS. Treatment of post-inflammatory hyperpigmentation using 1064-nm Q-switched Nd:YAG laser with low fluence: report of three cases. J Eur Acad Dermatol Venereol. 2009;23(10):1206-1207.
52. Cho SB, Lee JH, Lee SH, Lee SJ, Bang D, Oh SH. Efficacy and safety of 1064-nm Q-switched Nd:YAG laser with low fluence for keloids and hypertrophic scars. J Eur Acad Dermatol Venereol. 2010;24(9):1070-1074.
53. Badawi A, Tome MA, Atteya A, Sami N, Morsy IA. Retrospective analysis of nonablative scar treatment in dark skin types using the sub-millisecond Nd:YAG 1,064nm laser. Lasers Surg Med. 2011;43(2):130-136.
54. Haedersdal M. Fractional ablative CO(2) laser resurfacing improves a thermal burn scar. J Eur Acad Dermatol Venereol. 2009;23(11):1340-1341.
55. Manstein D, Herron GS, Sink RK, Tanner H, Anderson RR. Fractional photothermolysis: a new concept for cutaneous remodeling using microscopic patterns of thermal injury. Lasers Surg Med. 2004;34(5):426-438. (Pubitemid 38890753)
56. Behroozan DS, Goldberg LH, Dai T, Geronemus RG, Friedman PM. Fractional photothermolysis for the treatment of surgical scars: a case report. J Cosmet Laser Ther. 2006;8(1):35-38.
57. Kunishige JH, Katz TM, Goldberg LH, Friedman PM. Fractional photothermolysis for the treatment of surgical scars. Dermatol Surg. 2010;36(4):538-541.
58. Glaich AS, Rahman Z, Goldberg LH, Friedman PM. Fractional resurfacing for the treatment of hypopigmented scars: a pilot study. Dermatol Surg. 2007; 33(3):289-294. (Pubitemid 46328221)
59. Tierney E, Mahmoud BH, Srivastava D, Ozog D, Kouba DJ. Treatment of surgical scars with nonablative fractional laser versus pulsed dye laser: a randomized controlled trial. Dermatol Surg. 2009;35(8):1172-1180.
60. Pham AM, Greene RM, Woolery-Lloyd H, Kaufman J, Grunebaum LD. 1550-nm nonablative laser resurfacing for facial surgical scars. Arch Facial Plast Surg. 2011;13(3):203-210.
61. Metelitsa AI, Alster TS. Fractionated laser skin resurfacing treatment complications: a review. Dermatol Surg. 2010;36(3):299-306.
62. Fife DJ, Zachary CB. Delayed pinpoint purpura after fractionated carbon dioxide treatment in a patient taking ibuprofen in the postoperative period. Dermatol Surg. 2009;35(3):553.
63. Chan HH, Manstein D, Yu CS, Shek S, Kono T, Wei WI. The prevalence and risk factors of post-inflammatory hyperpigmentation after fractional resurfacing in Asians. Lasers Surg Med. 2007;39(5):381-385. (Pubitemid 47041086)
64. Chang CC, Kuo YF, Chiu HC, Lee JL, Wong TW, Jee SH. Hydration, not silicone, modulates the effects of keratinocytes on fibroblasts. J Surg Res. 1995; 59(6):705-711.
65. Suetak T, Sasai S, Zhen YX, Tagami H. Effects of silicone gel sheet on the stratum corneum hydration. Br J Plast Surg. 2000;53(6):503-507. (Pubitemid 30649045)
66. Hanasono MM, Lum J, Carroll LA, Mikulec AA, Koch RJ. The effect of silicone gel on basic fibroblast growth factor levels in fibroblast cell culture. Arch Facial Plast Surg. 2004;6(2):88-93.
67. Kuhn MA, Moffit MR, Smith PD, et al. Silicone sheeting decreases fibroblast activity and downregulates TGFbeta2 in hypertrophic scar model. Int J Surg Investig. 2001;2(6):467-474.
68. Gallant-Behm CL, Mustoe TA. Occlusion regulates epidermal cytokine production and inhibits scar formation. Wound Repair Regen. 2010;18(2):235-244.
69. Tandara AA, Kloeters O, Mogford JE, Mustoe TA. Hydrated keratinocytes reduce collagen synthesis by fibroblasts via paracrine mechanisms. Wound Repair Regen. 2007;15(4):497-504. (Pubitemid 47087642)
70. Tandara AA, Mustoe TA. The role of the epidermis in the control of scarring: evidence for mechanism of action for silicone gel. J Plast Reconstr Aesthet Surg. 2008;61(10):1219-1225.
71. Gilman TH. Silicone sheet for treatment and prevention of hypertrophic scar: a new proposal for the mechanism of efficacy. Wound Repair Regen. 2003; 11(3):235-236. (Pubitemid 36648883)
72. Brown NJ, Smyth EA, Cross SS, Reed MW. Angiogenesis induction and regression in human surgical wounds. Wound Repair Regen. 2002;10(4): 245-251. (Pubitemid 35006786)
73. O'Brien L, Pandit A. Silicon gel sheeting for preventing and treating hypertrophic and keloid scars. Cochrane Database Syst Rev. 2006;(1):CD003826.
74. O'Shaughnessy KD, De La Garza M, Roy NK, Mustoe TA. Homeostasis of the epidermal barrier layer: a theory of how occlusion reduces hypertrophic scarring. Wound Repair Regen. 2009;17(5):700-708.
75. de Giorgi V, Sestini S, Mannone F, et al. The use of silicone gel in the treatment of fresh surgical scars: a randomized study. Clin Exp Dermatol. 2009;34 (6):688-693.
76. Li-Tsang CW, Zheng YP, Lau JC. A randomized clinical trial to study the effect of silicone gel dressing and pressure therapy on posttraumatic hypertrophic scars. J Burn Care Res. 2010;31(3):448-457.
77. van der Wal MB, van Zuijlen PP, van de Ven P, Middelkoop E. Topical silicone gel versus placebo in promoting the maturation of burn scars: a randomized controlled trial. Plast Reconstr Surg. 2010;126(2):524-531.
78. Linares HA, Larson DL, Willis-Galstaun BA. Historical notes on the use of pressure in the treatment of hypertrophic scars or keloids. Burns. 1993;19(1): 17-21. (Pubitemid 23059384)
79. Jensen LL, Parshley PF. Postburn scar contractures: histology and effects of pressure treatment. J Burn Care Res. 1984;5(2):119-123. (Pubitemid 14104699)
80. Costa AMA, Peyrol S, Pôrto LC, Comparin JP, Foyatier JL, Desmoulière A. Mechanical forces induce scar remodeling: study in non-pressure-treated versus pressure-treated hypertrophic scars. Am J Pathol. 1999;155(5):1671-1679.
81. Grinnell F. Fibroblasts, myofibroblasts, and wound contraction. J Cell Biol. 1994; 124(4):401-404. (Pubitemid 24064453)
82. Baur PS, Larson DL, Stacey TR. The observation of myofibroblasts in hypertrophic scars. Surg Gynecol Obstet. 1975;141(1):22-26.
83. Liu XS, Luo ZH, Yang ZC, Li AN. Clinical significance of the alterations of plasma prostaglandin E2 (PGE2) in severely burned patients. Burns. 1996;22(4): 298-302.
84. Renò F, Grazianetti P, Cannas M. Effects of mechanical compression on hypertrophic scars: prostaglandin E2 release. Burns. 2001;27(3):215-218. (Pubitemid 32328300)
85. Chang LW, Deng WP, Yeong EK, Wu CY, Yeh SW. Pressure effects on the growth of human scar fibroblasts. J Burn Care Res. 2008;29(5):835-841.
86. Groce A, Herndon DN, McCauley RL, et al. The effects of pressure vs no pressure garments in the control of hypertrophic scarring in children with small burns: a preliminary 6 month report [abstract]. J Burn Care Rehabil. 2000;21:S178.
87. Staley MJ, Richard RL. Use of pressure to treat hypertrophic burn scars. Adv Wound Care. 1997;10(3):44-46.
88. Reid WH, Evans JH, Naismith RS, Tully AE, Sherwin S. Hypertrophic scarring and pressure therapy. Burns Incl Therm Inj. 1987;13(suppl):S29-S32.
89. Ward RS. Pressure therapy for the control of hypertrophic scar formation after burn injury: a history and review. J Burn Care Rehabil. 1991;12(3):257-262.
90. Borok TL, Bray M, Sinclair I, Plafker J, LaBirth L, Rollins C. Role of ionizing irradiation for 393 keloids. Int J Radiat Oncol Biol Phys. 1988;15(4):865-870.
91. Ogawa R, Mitsuhashi K, Hyakusoku H, Miyashita T. Postoperative electronbeam irradiation therapy for keloids and hypertrophic scars: retrospective study of 147 cases followed for more than 18 months. Plast Reconstr Surg. 2003; 111(2):547-555.
92. Slemp AE, Kirschner RE. Keloids and scars: a review of keloids and scars, their pathogenesis, risk factors, and management. Curr Opin Pediatr. 2006;18 (4):396-402. (Pubitemid 44258997)
93. Mustoe TA, Cooter RD, Gold MH, et al; International Advisory Panel on Scar Management. International clinical recommendations on scar management. Plast Reconstr Surg. 2002;110(2):560-571. (Pubitemid 34815962)
94. Recalcati S, Caccialanza M, Piccinno R. Postoperative radiotherapy of auricular keloids: a 26-year experience. J Dermatolog Treat. 2011;22(1):38-42.
95. van de Kar AL, Kreulen M, van Zuijlen PP, Oldenburger F. The results of surgical excision and adjuvant irradiation for therapy-resistant keloids: a prospective clinical outcome study [published correction appears in Plast Reconstr Surg. 2007;120(2):579]. Plast Reconstr Surg. 2007;119(7):2248-2254.
96. Van Den Brenk HA, Minty CC. Radiation in the management of keloids and hypertrophic scars. Br J Surg. 1960;47:595-605.
97. Malaker K, Vijayraghavan K, Hodson I, Al Yafi T. Retrospective analysis of treatment of unresectable keloids with primary radiation over 25 years. Clin Oncol (R Coll Radiol). 2004;16(4):290-298. (Pubitemid 38696971)
98. Thomas JR, Mobley SR. Scar revision and camouflage. In: Flint PW, Haughey BJ, Lund VJ, Niparko JK, eds. Cummings Otolaryngology Head and Neck Surgery. St Louis, MO: Mosby; 2010:299.
99. Harmon CB. Dermabrasion. Dermatol Clin. 2001;19(3):439-442, viii. (Pubitemid 32924286)
100. Kokoska M, Thomas JR. Scar revision. In: Papel I, ed. Facial Plastic and Reconstructive Surgery. New York, NY: Thieme; 2009:64.
101. Bradley DT, Park SS. Scar revision via resurfacing. Facial Plast Surg. 2001;17 (4):253-262.
102. Poulos E, Taylor C, Solish N. Effectiveness of dermasanding (manual dermabrasion) on the appearance of surgical scars: a prospective, randomized, blinded study. J Am Acad Dermatol. 2003;48(6):897-900. (Pubitemid 36706224)
103. Gillard M, Wang TS, Boyd CM, Dunn RL, Fader DJ, Johnson TM. Conventional diamond fraise vs manual spot dermabrasion with drywall sanding screen for scars from skin cancer surgery. Arch Dermatol. 2002;138(8):1035-1039. (Pubitemid 34875607)
104. Sun Y, Ratajska A, Zhou G, Weber KT. Angiotensin-converting enzyme and myocardial fibrosis in the rat receiving angiotensin II or aldosterone. J Lab Clin Med. 1993;122(4):395-403. (Pubitemid 23346774)
105. Schnee JM, Hsueh WA. Angiotensin II, adhesion, and cardiac fibrosis. Cardiovasc Res. 2000;46(2):264-268.
106. Steckelings UM, Wollschläger T, Peters J, Henz BM, Hermes B, Artuc M. Human skin: source of and target organ for angiotensin II. Exp Dermatol. 2004; 13(3):148-154. (Pubitemid 38380278)
107. Morihara K, Takai S, Takenaka H, et al. Cutaneous tissue angiotensinconverting enzymemay participate in pathologic scar formation in human skin. J Am Acad Dermatol. 2006;54(2):251-257. (Pubitemid 43144394)
108. Tang HT, Cheng DS, Jia YT, et al. Angiotensin II induces type I collagen gene expression in human dermal fibroblasts through an AP-1/TGF-beta1-dependent pathway. Biochem Biophys Res Commun. 2009;385(3):418-423.
109. Yahata Y, Shirakata Y, Tokumaru S, et al. A novel function of angiotensin II in skin wound healing. Induction of fibroblast and keratinocyte migration by angiotensin II via heparin-binding epidermal growth factor (EGF)-like growth factormediated EGF receptor transactivation. J Biol Chem. 2006;281(19):13209- 13216. (Pubitemid 43855232)
110. Iannello S, Milazzo P, Bordonaro F, Belfiore F. Low-dose enalapril in the treatment of surgical cutaneous hypertrophic scar and keloid-two case reports and literature review. MedGenMed. 2006;8(4):60.
111. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem. 2000;69:145-182.
112. Pentland AP, Mahoney M, Jacobs SC, Holtzman MJ. Enhanced prostaglandin synthesis after ultraviolet injury is mediated by endogenous histamine stimulation: a mechanism for irradiation erythema. J Clin Invest. 1990;86(2):566-574. (Pubitemid 20271892)
113. Marks F, Fürstenberger G. Proliferative responses of the skin to external stimuli. Environ Health Perspect. 1993;101(suppl 5):95-101. (Pubitemid 24096331)
114. Lupulescu A. Effect of prostaglandins on protein, RNA, DNA and collagen synthesis in experimental wounds. Prostaglandins. 1975;10(4):573-579.
115. Durant S, Duval D, Homo-Delarche F. Effect of exogenous prostaglandins and nonsteroidal anti-inflammatory agents on prostaglandin secretion and proliferation of mouse embryo fibroblasts in culture. Prostaglandins Leukot Essent Fatty Acids. 1989;38(1):1-8. (Pubitemid 19263131)
116. Talwar M, Moyana TN, Bharadwaj B, Tan LK. The effect of a synthetic analogue of prostaglandin E2 on wound healing in rats. Ann Clin Lab Sci. 1996;26 (5):451-457. (Pubitemid 26296344)
117. Wilgus TA, Vodovotz Y, Vittadini E, Clubbs EA, Oberyszyn TM. Reduction of scar formation in full-thickness wounds with topical celecoxib treatment. Wound Repair Regen. 2003;11(1):25-34. (Pubitemid 36268606)
118. Hoffman M, Pradhan S, Monroe DM. Celecoxib does not delay cutaneous wound healing in haemophilia B mice. Haemophilia. 2009;15(2):615-616.
119. Blomme EA, Chinn KS, Hardy MM, et al. Selective cyclooxygenase-2 inhibition does not affect the healing of cutaneous full-thickness incisional wounds in SKH-1 mice. Br J Dermatol. 2003;148(2):211-223. (Pubitemid 36278959)
120. Hardy MM, Blomme EA, Lisowski A, et al. Selective cyclooxygenase-2 inhibition does not alter keratinocyte wound responses in the mouse epidermis after abrasion. J Pharmacol Exp Ther. 2003;304(3):959-967. (Pubitemid 36254406)
121. Kämpfer H, Bräutigam L, Geisslinger G, Pfeilschifter J, Frank S. Cyclooxygenase-1-coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair. J Invest Dermatol. 2003;120(5):880-890. (Pubitemid 36529093)
122. Su WH, Cheng MH, Lee WL, et al. Nonsteroidal anti-inflammatory drugs for wounds: pain relief or excessive scar formation? Mediators Inflamm. 2010; 2010:413238.
123. Müller-Decker K, Hirschner W, Marks F, Fürstenberger G. The effects of cyclooxygenase isozyme inhibition on incisional wound healing in mouse skin. J Invest Dermatol. 2002;119(5):1189-1195. (Pubitemid 35430498)
124. O'Kane S, Ferguson MW. Transforming growth factor beta s and wound healing. Int J Biochem Cell Biol. 1997;29(1):63-78. (Pubitemid 27096420)
125. Bandyopadhyay B, Fan J, Guan S, et al. A "traffic control" role for TGFbeta3: orchestrating dermal and epidermal cell motility during wound healing. J Cell Biol. 2006;172(7):1093-1105.
126. Occleston NL, Laverty HG, O'Kane S, Ferguson MW. Prevention and reduction of scarring in the skin by transforming growth factor beta 3 (TGFbeta3): from laboratory discovery to clinical pharmaceutical. J Biomater Sci Polym Ed. 2008; 19(8):1047-1063. (Pubitemid 351957390)
127. Bayat A, McGrouther DA, Ferguson MW. Skin scarring. BMJ. 2003;326(7380): 88-92. (Pubitemid 36092292)
128. Cowin AJ, Holmes TM, Brosnan P, Ferguson MW. Expression of TGF-beta and its receptors in murine fetal and adult dermal wounds. Eur J Dermatol. 2001; 11(5):424-431. (Pubitemid 32801338)
129. Ohno S, Hirano S, Kanemaru S, et al. Prevention of buccal mucosa scarring with transforming growth factor-3. Laryngoscope. 2011;121(7):1404-1409.
130. Waddington SN, Crossley R, Sheard V, et al. Gene delivery of a mutant TGF-3 reduces markers of scar tissue formation after cutaneous wounding. Mol Ther. 2010;18(12):2104-2111.
131. Shah M, Foreman DM, Ferguson MW. Neutralisation of TGF-beta 1 and TGFbeta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. J Cell Sci. 1995;108(pt 3):985-1002.
132. Ferguson MW, Duncan J, Bond J, et al. Prophylactic administration of avotermin for improvement of skin scarring: three double-blind, placebo-controlled, phase I/II studies. Lancet. 2009;373(9671):1264-1274.
133. Bush J, Duncan JA, Bond JS, et al. Scar-improving efficacy of avotermin administered into the wound margins of skin incisions as evaluated by a randomized, double-blind, placebo-controlled, phase II clinical trial. Plast Reconstr Surg. 2010;126(5):1604-1615.
134. So K, McGrouther DA, Bush JA, et al. Avotermin for scar improvement following scar revision surgery: a randomized, double-blind, within-patient, placebocontrolled, phase II clinical trial. Plast Reconstr Surg. 2011;128(1):163-172.
135. McCollum PT, Bush JA, James G, et al. Randomized phase II clinical trial of avotermin versus placebo for scar improvement. Br J Surg. 2011;98(7): 925-934.